Stockwinners Market Radar for October 17, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Pulse Biosciences to present data from studies of nano-pulse stimulation at ASDS - Pulse Biosciences announced that it will present results of three clinical studies demonstrating high clearance rates across its benign skin lesion portfolio during the upcoming American Society for Dermatologic Surgery, or ASDS, annual meeting on October 24-27, in Chicago. The data will span the company's CellFX procedure using NPS non-thermal energy in clearing Sebaceous Hyperplasia lesions, non-genital warts and back acne. The cellular-specific NPS technology was also selected to be featured at the opening Plenary Session, which highlights cutting-edge science and emerging therapies in dermatologic surgery.

18:49 EDT Fly Intel: After Hours Movers - UP AFTER EARNINGS: Marten Transport (MRTN) up 3.2%... Intuitive Surgical (ISRG) up 3.1%... E-Trade (ETFC) up 3.1%... Western Alliance (WAL) up 1.0%... Atlassian (TEAM) up 0.5%. ALSO HIGHER: Paratek (PRTK) up 5.5%. DOWN AFTER EARNINGS: Gildan (GIL) down 12.4% after negative Q3 pre-announcement... Brandywine Realty (BDN) down 10.9%... Exponent (EXPO) down 6.1%... WD-40 (WDFC) down 5.3%... Vicor Corp (VICR) down 3.6%... Bank OZK (OZK) down 2.0%. Movers as of 18:30ET.

18:32 EDT Sensient raises quarterly dividend 8.3% to 39c per share - The board of directors of Sensient Technologies has declared a regular quarterly cash dividend on its common stock of 39c per share, an increase of 8.3% per share. The cash dividend will be paid on December 2, 2019, to shareholders of record on November 4, 2019. "This increase raises our dividend payments to an annualized payout of $1.56 per share and reflects confidence in the future of our business," said Paul Manning, Chairman, President and Chief Executive Officer of Sensient Technologies Corporation. "With this increase, our quarterly dividend has risen by 56% over the past five years."

17:16 EDT Activision says Call of Duty to get 'battle pass' feature, 'not loot box system' - Activision's Call of Duty Staff said in a blog post: "Call of Duty: Modern Warfare is almost here. From the moment this project began three years ago, the energy has been extraordinary. We've set our sights on not only creating the best game possible this year, but also on breaking down walls and bringing the community together. Starting with Modern Warfare, we will be: Introducing crossplay to unite the community across platforms for the first time. Removing Season Pass and a la carte DLC multiplayer map packs to ensure everyone can play together. Delivering free post-launch multiplayer maps and modes for all player. Releasing post-launch multiplayer maps and modes simultaneously on all platforms. We are excited about what these changes will bring to Call of Duty players. That said, we also recognize there is one more topic that many fans are interested to learn more about. Today, let's address the basics for the in-game economy coming in Modern Warfare. We are introducing a new Battle Pass system, not a loot box system." Reference Link

17:10 EDT Brandywine Realty reports Q3 same-store net operating income up 0.6% - Reports Q3 occupancy 93.1%.

17:01 EDT Spirit Airlines announces $250M global HQ investment - Spirit Airlines announced its intention to build a state-of-the-art headquarters in Dania Beach, Florida. The company plans to move into the new campus by mid-2022. The airline submitted site plans to the City of Dania Beach to build a campus up to 500,000 square feet act Dania Pointe, a premier mixed-use development comprised of nearly one million square feet of retail space, restaurants and housing.

16:54 EDT Intuitive Surgical says 79% of systems placed in Q3 were da Vinci XIs - Says surgical simulation products have been widely accepted. Says Q3 procedures grew 20% year-over-year. Says procedure growth remains driven by general surgery in the U.S. and urology worldwide. Says expects return of medical device tax in 2020. Comments taken from Q3 earnings conference call.

16:49 EDT Assured Guaranty officer Andrew Feldstein buys 23,400 shares of company stock - Assured Guaranty officer Andrew Feldstein disclosed in a filing that he had purchased 23,400 shares of company stock at an average price of $46.27 per share between October 15 and October 16. The total transaction value of the purchase was $1,082,601.

16:39 EDT Monster Beverage says U.S court denies ViPX's preliminary injunction motion - Monster Energy and Reign Beverage reported that the US District Court for the Southern District of Florida yesterday issued its decision denying the baseless motion for a preliminary injunction filed by Vital Pharmaceuticals d/b/a VPX Sports against Monster and Reign's Reign Total Body Fuel performance energy drinks. In denying VPX's motion, the Court ruled that "VPX has failed to meet any of the elements of a preliminary injunction" and that "VPX has failed to establish that it is likely to succeed on the merits [of its claims against Monster and Reign-and, therefore, a preliminary injunction is unwarranted." In view of the Court's Order, VPX cannot interrupt distributors' and retailers' right to sell Reign Total Body Fuel performance energy drinks. The Court's ruling also strongly supports Monster's and Reign's previously stated belief that they will ultimately prevail against VPX's frivolous claims in this lawsuit.

16:35 EDT Covenant Transportation trading resumes

16:23 EDT Transocean added approximately $75M in contract backlog - Transocean issued a quarterly Fleet Status Report that provides the current status of, and contract information for, the company's fleet of offshore drilling rigs. Since its last report Transocean added approximately $75 million in contract backlog, bringing total backlog to $10.8 billion.This quarter's report includes the following new contracts:Paul B. Loyd, Jr. - Awarded an estimated 255 day contract in the UK North Sea; Deepwater Nautilus - Awarded a 45 day contract in Brunei; and Discoverer India - Customer exercised a one-well option in Egypt.

16:21 EDT USA Technologies CEO Steve Herbert to step down, Donald Layden named interim CEO - USA Technologies announced that its board has appointed current board member, Donald Layden, as interim CEO, effective immediately. Layden's appointment follows Stephen Herbert's decision to step down as CEO and a director of the company. The company intends to engage an executive search firm to identify a permanent CEO.

16:19 EDT Natus Medical to transition Peloton hearing business to Pediatrix Medical - Natus Medical Iannounced that the company signed a definitive agreement to transition its Peloton hearing screening services business to Pediatrix Medical Group. After the completion of the transition, Pediatrix will manage all newborn hearing screening services for Peloton hospitals. As part of the transition, Natus and Pediatrix have entered into a strategic agreement where Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business. Upon completion of this transition, Pediatrix will provide hearing screening services to over 500 U.S. hospitals. "We are pleased to partner with an industry leader like Pediatrix to carry on our practice of newborn hearing screening service into the future," said Jonathan Kennedy, President and Chief Executive Officer of Natus. "This partnership allows us to continue to supply our world-class screening devices and supplies to the hearing screening business through our strategic agreement with Pediatrix." "We are excited to add the Peloton customers to our existing portfolio of hospitals benefiting from our leading healthcare solutions, and we believe we can add tremendous value in these new relationships," said Roger M. Hinson, M.D., President of Pediatrix and Obstetrix Medical Groups. The transition of the Peloton business is expected to be complete by the end of the fourth quarter of 2019. Installation of ALGO screeners at the Pediatrix hospitals will be completed during 2020.

16:17 EDT Bluegreen Vacations appoints Dusty Tonkin CSO - Bluegreen Vacations announced that Dusty Tonkin has been appointed the company's new chief sales officer, or CSO. As CSO, Tonkin will oversee Bluegreen Vacations' field sales and marketing operations. He will be integral in growing the company's VOI sales as well as leading all sales-focused strategic initiatives. Tonkin is a sales executive who has worked in the vacation ownership industry for more than 24 years. He comes to Bluegreen Vacations from Wyndham Destinations, where he served in various sales leadership roles since 2002, most recently as executive VP of sales & marketing where he led teams in six major regions.

16:15 EDT Dermira presents primary results from phase 2b lebrikizumab study - Dermira announced that primary results from its Phase 2b dose-ranging study of lebrikizumab are being presented during the Fall Clinical Dermatology Conference. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderate-to-severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with very high affinity, specifically preventing the formation of the IL-13Ralpha1/IL-4Ralpha heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening and infection. The randomized, double-blind, placebo-controlled, parallel-group Phase 2b study was designed to evaluate the safety and efficacy of lebrikizumab as monotherapy compared with placebo and establish a dosing regimen for the Phase 3 program in patients with moderate-to-severe atopic dermatitis. The study enrolled 280 patients ages 18 years and older with moderate-to-severe atopic dermatitis at 57 sites in the United States. The inclusion criteria for patients enrolled in this study included the presence of chronic atopic dermatitis for at least one year, an Eczema Area and Severity Index, or EASI, score of 16 or greater, an Investigator's Global Assessment, or IGA, score of 3 or 4 and body surface area, or BSA, involvement of at least 10 percent at screening and baseline.The primary endpoint of the study was the percent change in EASI from baseline to week 16. Secondary endpoints that were evaluated during the 16-week treatment period included: the proportion of patients with a 75% improvement from baseline in EASI score; the proportion of patients with a reduction of 2 or more points in IGA score from baseline to a final score of 0 or 1; the proportion of patients achieving EASI-50 and EASI-90; changes in pruritus and sleep loss scores from baseline, each scored using a numerical rating scale and the proportion of patients with an improvement in pruritus NRS score of at least 4 points from baseline. Initial topline findings from the Phase 2b study were previously announced in March, showing that across all doses evaluated, lebrikizumab demonstrated dose-dependent and statistically significant improvements in the primary endpoint, the mean percent change in EASI score from baseline to week 16. The data being presented highlight secondary endpoints assessing measures spanning the range of signs and symptoms of atopic dermatitis, including skin lesions and pruritus over the 16-week treatment period. A response was observed as early as the first on-treatment visit at week 4 for all atopic dermatitis severity scores. Lebrikizumab demonstrated a dose-dependent response across each of the EASI-50, EASI-75, EASI-90 and IGA0/1 endpoints, with marked improvement at both the 250 mg every two weeks and 250 mg every four weeks doses. As expected, based on prior experience, lebrikizumab was generally well-tolerated, with a safety profile consistent with that observed in prior studies in more than 4,000 patients. Adverse events observed in lebrikizumab-treated patients were primarily mild to moderate in severity and infrequently led to treatment discontinuation. The most common adverse events reported across the lebrikizumab 250mg Q2W, 250mg Q4W and 125mg Q4W dosing arms were upper respiratory tract infection, nasopharyngitis, headache and injection site pain. Rates of herpes viral infections were 2.7%, 5.0% and 2.7%, respectively, vs. 3.8% for placebo and conjunctivitis were low. Across all studies of lebrikizumab conducted to date in atopic dermatitis, conjunctivitis has been reported at low rates similar to those in patients receiving placebo. Based on the Phase 2b study results, Dermira recently announced the initiation of a Phase 3 clinical development program to further evaluate lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis.

16:09 EDT WD-40 sees FY20 gross margin 54%-55%

16:08 EDT Huntington Bancshares names Zachary Wasserman as CFO, effective November 4 - Huntington Bancshares (HBAN) that Zachary Wasserman will become Huntington's senior executive vice president and CFO, effective November 4. In this role, Wasserman will be responsible for finance, strategic planning, mergers and acquisitions, investor relations, treasury, tax and accounting. He will report to Stephen Steinour, chairman, president and CEO of Huntington. Wasserman succeeds Howell "Mac" McCullough, who previously announced his planned retirement after more than five years as Huntington's CFO. McCullough's retirement is effective on December 31, 2019, providing time for a smooth transition for Wasserman. Wasserman joins Huntington from Visa (V) where he served as CFO for the company's North American business. In this role, he led all aspects of financial management, including financial planning and analysis, strategic planning, fintech initiatives, mergers and acquisitions and portfolio optimization.

16:07 EDT Safe-T receives Nasdaq notification on minimum bid requirements - Safe-T received a written notice from Nasdaq indicating that the company was not in compliance with Nasdaq listing rules as the company's closing bid price for its ADSs was below $1.00 per share for the 30 consecutive business days prior to the Notice. The company has been granted a 180-calendar day compliance period, or until April 8, 2020, to regain compliance with the minimum bid price requirement. During the compliance period, the company's ADSs will continue to be listed and traded on Nasdaq. To regain compliance, the closing bid price of the company's ADSs must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. On October 7, the company approved a 20-for-1 reverse split of the company's share capital. The reverse split will be effective on Nasdaq on October 22. Safe-T expects to regain compliance with the minimum bid price requirement in connection with its scheduled reverse split.

16:03 EDT Covenant Transportation trading halted, news pending

15:31 EDT Goldman CEO says bank still profitable on WeWork investment - Goldman Sachs (GS) CEO David Solomon said in an interview on CNBC that there has been a "more lax" approach to governance at WeWork (WE) than he would prefer. Solomon added that although the IPO fell through, the process did not break down and actually worked as intended. The CEO also said that the bank is still profitable on its WeWork investment. He added that markets make judgements around "what's appropriate" for IPO valuations.

15:01 EDT Innophos Holdings jumps after Bloomberg says PE firm near takeover agreement - Shares of Innophos Holdings have jumped 12% in late day trading after Bloomberg reported that private equity firm One Rock Capital Partners is in advanced talks to buy the food additives maker. People familiar with the matter told Bloomberg that no transaction has been finalized and talks could fall through, the report added. Shares of Innophos were halted for volatility following Bloomberg's report.

14:50 EDT SL Green Realty CEO says 'well ahead of schedule on leasing volume' - SL Green Realty CEO Marc Holliday said on the company's Q3 earnings call: "On the leasing front, we are well ahead of schedule on leasing volume and projected mark-to-market, which is closing our FFO to the trending toward the high side of our estimated range, notwithstanding the aggressive dispositions and intended reductions in debt and preferred equity portfolio, both dilutive activities as of setting in part by reduction in stock buyback. With another 71,000 square feet of Manhattan office space leased so far by us in our portfolio in October, we now stand at 1.25 million square feet leased for 2019. Now add another 260,000 square feet of leases that are out for signature with signings expected imminently, plus an additional 1.4 million square feet of leasing pipeline on top of this, and we have the makings of what we hope will be a very big year-end for this company. We expect to add nearly 100 basis points of occupancy between now and year-end, bringing us to our original goal for the year and at 22% mark-to-market on our Manhattan leases, which is where we are currently, we are far ahead of our goal and expect to improve on that by year-end."

14:23 EDT SmileDirectClub down 7% following short-seller tweet about 'raid' on stores - Shares of SmileDirectClub (SDC) are down 70c, or 7%, to $9.30 in afternoon trading after Hindenburg Research, which published a short report regarding SmileDirectClub on October 4, tweeted: "INCREDIBLE: $SDC ADMITS in a newly filed lawsuit that its SmileShops were RAIDED 'state-wide' by the Dental Board of California (part of CA Dept. of Consumer Affairs)" along with a link to a case docket. The Fly has reached out to SmileDirectClub for comment on the lawsuit and short seller's claims. In its previously published short report, Hindenburg Research asserted its view that SmileDirectClub "is carelessly cutting corners in a field of specialized medicine, putting customer safety at risk." The firm set a one-year price target of $2 on the stock. On the day the report was published, the company stated in part: "Recently, there have been media statements by dental trade organizations and allegations in a class action lawsuit filed in Nashville federal court that purports to question the safety and legitimacy of SmileDirectClub's pioneering teledentistry platform. There is no factual basis nor scientific or medical justification in these allegations to substantiate the false claims made about our model and the state-licensed doctors in our affiliated network."

13:53 EDT PPG says U.S., Canada sales down low-single digit percentage in Q3 - PPG Industries said in prepared remarks ahead of its Q3 earnings call: "In the U.S. and Canada region, sales volumes were down by a low-single-digit percentage. Aerospace coatings had strong, above-market sales volume performance. In addition, sales volumes for U.S. and Canada architectural coatings national retail do-it-for-yourself and independent dealer channels and for marine coatings were positive. Softer sales volumes in all other businesses more than offset these gains... Sales volumes were lower by a low-single-digit percent in the Europe, Middle East, and Africa region compared to the prior year, driven by sharply lower industrial production compared to the same period last year... Industrial production remained soft in the Asia-Pacific region during the third quarter, which led to sales volumes declining by a mid-single-digit percentage year-over-year... In Latin America, sales volumes were lower by a mid-single-digit percent versus the prior year driven by soft economic demand in Mexico and Central America. Sales volumes were higher in several South American countries and were particularly strong in Brazil."

13:06 EDT Houghton Mifflin to cut 8% of workforce, to take $12M-$16M charges - At its 2019 Analyst and Investor Event, Houghton Mifflin will provide additional detail about its long-term strategy and steps the company is taking to simplify its business model and accelerate growth. This includes the announcement of actions that are creating new product development and go-to-market capabilities, as well as the streamlining of operations company-wide for greater efficiency. These actions are expected to result in the elimination of 8% of HMH's workforce, after taking into account new strategy-aligned positions that are expected to be added and additional operating and capitalized cost reductions, including a redesigned product development model that is expected to result in approximately 20% less content development expenditures than previously planned over the next three years starting in 2020. These steps are intended to further simplify HMH's business model while delivering increased value to customers, teachers and students. Total charges associated with these actions are estimated to be in a range of $12 million to $16 million.

12:47 EDT Entertainment One shareholders vote in favor of acquisition by Hasbro - Hasbro (HAS) announced that Entertainment One (ENTMF) shareholders have voted to approve the proposal for Hasbro to acquire eOne in an all-cash transaction valued at approximately $4B, pursuant to the definitive arrangement agreement between the parties. More than 99.9% of the votes cast at the eOne special meeting of shareholders held earlier today voted in favor of the transaction. The transaction, which is structured as a statutory plan of arrangement under the Canada Business Corporations Act, remains subject to receipt of certain regulatory approvals and other customary closing conditions including a final order of the Ontario Superior Court of Justice. The transaction has received several regulatory approvals so far, including early termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act in the U.S. and antitrust approval in Germany. The transaction is expected to close during the fourth quarter of 2019.

12:34 EDT AzurRx BioPharma says CFF DSMB review of Phase 2 trial found no safety concerns - AzurRx BioPharma announced that the Cystic Fibrosis Foundation, or CFF, Data Safety Monitoring Board, or DSMB, has completed its review of the company's final results of the Phase 2 OPTION trial and has found no safety concerns for MS1819-SD. Additionally, the group supports the company's plan to proceed to a higher 4-gram dose of MS1819-SD in its next planned Phase 2 clinical trial. James Sapirstein, CEO of AzurRx said, "The positive safety review of the CFF DSMB is an important milestone for the development of MS1819-SD as a monotherapy and for the AzurRx team. We look forward to our planned meeting with the FDA in December and to initiating our next Phase 2 study of MS1819-SD at a higher dose in early 2020."

12:04 EDT Endo rises as Citron says double possible if opioid settlement reports true - Shares of Endo (ENDP) are up 79c, or 19%, to $4.95 following media reports about potential talks to settle opioid litigation. Citron Research, the firm run by Andrew Left, tweeted minutes ago that the market is "realizing that $ENDP is the real beneficiary of opioid settlement as reported," adding "If reporting is true $ENDP can be $10 on Mon." The tweet also refers to Endo as "the anti-Mallinckrodt," which is a pharmaceutical maker that Left has previously been critical on and recommended shorting. Reference Link

12:00 EDT Direxion Daily Gold Miners Bear 3X ETF falls -6.0% - Direxion Daily Gold Miners Bear 3X ETF is down -6.0%, or -48c to $7.59.

12:00 EDT Crown Holdings rises 8.4% - Crown Holdings is up 8.4%, or $5.34 to $68.87.

12:00 EDT C&J Energy Services rises 11.7% - C&J Energy Services is up 11.7%, or 90c to $8.57.

11:23 EDT Foamix announces FDA acceptance of FMX103 drug application - Foamix Pharmaceuticals announced that the Food and Drug Administration has accepted for review the New Drug Application for FMX103 topical foam. Foamix is seeking approval of FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults. The FDA has set June 2, 2020 as the Prescription Drug User Fee Act action date. "The FDA's acceptance of the FMX103 NDA is another important milestone for Foamix as the company evolves into a fully integrated pharmaceutical company with clinical, development, and commercial capabilities. We look forward to working closely with the FDA throughout the review process," said David Domzalski, CEO.

11:06 EDT Choice Hotels signs 10-year extension with Choice Hotels Japan - Choice Hotels has signed a 10-year extension of its existing master franchising agreement with Choice Hotels Japan and expects to open more than 30 new Comfort hotels in the market by 2033. Choice Hotels Japan has been the exclusive franchisor of the Comfort brand in the country since 2003 and has a current portfolio of more than 60 hotels in markets including Tokyo, Yokohama, Osaka and Sapporo, the company added. The first seven of the new Comfort hotels are planned to open over the next three years in large cities including Kyoto, Matsuyama and Nagoya.

10:43 EDT Waitr Holdings sinks below $1 after CFO, board members resign - Shares of Waitr Holdings, an on-demand food ordering and delivery platform, are sinking after the company last night announced the resignation of its Chief Financial Officer Jeff Yurecko and two board members, Sue Collyns and Scott Fletcher. Waitr has initiated a search process to select a CFO and new board members. "Jeff, Sue and Scott's decisions to resign were not related to a disagreement with the Company over any of its operations, policies or practices," the company said in a statement. Adam Price, Chief Executive Officer, added, "Waitr's unique relationship-based approach, through a three-sided marketplace, as well as the front runner position we have in many of the markets we serve has provided a stable foundation for the Company. I continue to be excited about the improvement opportunities sitting in front of the business that we are looking to take advantage of over the next 6, 12 and 24 months." Shares of Waitr Holdings are down 36%, or 40c, to 71c in morning trading.

10:00 EDT VelocityShares 3x Inv Natural Gas ETN falls -4.1% - VelocityShares 3x Inv Natural Gas ETN is down -4.1%, or -$5.89 to $136.61.

10:00 EDT IBM falls -6.0% - IBM is down -6.0%, or -$8.57 to $133.53.

10:00 EDT Alcoa rises 9.7% - Alcoa is up 9.7%, or $1.85 to $21.01.

09:57 EDT Philip Morris says vaping headlines give IQOS 'even more of a chance' in U.S.

09:47 EDT Textron falls -4.9% - Textron is down -4.9%, or -$2.49 to $47.98.

09:47 EDT Xenia Hotels falls -6.6% - Xenia Hotels is down -6.6%, or -$1.37 to $19.36.

09:47 EDT Crown Holdings rises 8.6% - Crown Holdings is up 8.6%, or $5.48 to $69.01.

09:45 EDT CBS to delist shares when Viacom merger is complete - CBS (CBS) disclosed that its board determined that, effective as of, and conditional on the occurrence of, the effective time of the merger with Viacom (VIAB), CBS will voluntarily delist its common stock from the NYSE and will list the ViacomCBS shares, including the shares of CBS issued and outstanding immediately prior to the effective time of the merger. CBS expects that the ViacomCBS class A common stock and ViacomCBS class B common stock will be listed on Nasdaq under the new ticker symbols "VIACA" and "VIAC," respectively. Shares of CBS are down 4.5% to $36.39 in early trading while Viacom is down 4.5% to $21.81.

09:26 EDT Honeywell sees productivity products returning to growth in FY20

09:18 EDT Castor Maritime announces vessel acquisition for $10.2M - Castor Maritime announced that on October 14, 2019, through a separate wholly-owned subsidiary, it has entered into an agreement to purchase a 2005 Japan built Panamax dry bulk carrier for a purchase price of $10.2M from a third party in which a family member of Castor's chairman, CEO and CFO has an interest. The acquisition is expected to be consummated by taking delivery of the vessel by the end of October 2019 and is subject to the satisfaction of certain customary closing conditions.

09:14 EDT TrueCar, Motor1.com partner to launch auto buying program - Motor1.com and TrueCar have partnered to offer TrueCar's car buying platform to Motor1.com USA's 10 million unique monthly users who visit the site for its rich automotive content. The new Motor1.com Auto Buying Program, powered by TrueCar, provides Motor1.com USA's visitors with an efficient and transparent way to buy their next vehicle and will be accessible through various entry points on Motor1.com's homepage, article pages, and new car reviews.

09:11 EDT Bassett Furniture to purchase assets of Crimson Casual for $2.25M - Bassett Furniture Industries announced that it is finalizing an agreement to purchase certain assets of Crimson Casual, Inc. for $2,250,000 in cash and stock. Crimson Casual is a manufacturer and marketer of luxury aluminum outdoor furniture located in Haleyville, Alabama. With a state-of-the-art powder-coat finishing process, Crimson Casual can customize the frames with a number of different colors and finish textures. Bassett expects the transaction to be completed in early November 2019.

09:09 EDT Western Midstream declares Q3 distribution of 62c per share - WES declared a quarterly cash distribution of 62c per unit for Q3. This distribution is consistent with WES's 2019 annual distribution-growth guidance range of 5%-6%. WES's Q3 distribution is payable Nov. 13 to unitholders of record at the close of business Nov. 1.

09:07 EDT Invictus MD Strategies closes sale of Future Harvest Development - INVICTUS MD STRATEGIES announced the completion, effective October 16, 2019, of the previously announced sale of all the Company's shares of Future Harvest Development, which shares are held by the Company's wholly owned subsidiary Prestige Worldwide Holdings Inc. and comprise 82.5% of Future Harvest's total issued and outstanding shares, to SL 152 Ventures Ltd., a company owned by Mr. Byron Sheppard, a Director, President and CEO of Future Harvest, and whose company holds the remaining 17.5% of Future Harvest. The Company sought and received regulatory approval from the TSX Venture Exchange to close the Transaction.

09:04 EDT Bristol-Myers-Pfizer Alliance, Fitbit announce collaboration for AFib diagnosis - The Bristol-Myers Squibb (BMY)-Pfizer (PFE) Alliance and Fitbit (FIT) announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation, or AFib, with the aim of improving earlier detection in individuals at increased risk of stroke. The BMS-Pfizer Alliance and Fitbit plan to collaborate on the development of educational content and guidance to support people at increased risk for AFib. Upon submission and FDA clearance of the AFib detection software on Fitbit devices, the parties will aim to provide users with appropriate information to help encourage and inform discussions with their physicians.

09:04 EDT Comtech receives $1.6M satellite modem order from European MOD - Comtech Telecommunications announced that during Q1 of FY20, its Tempe, Arizona-based subsidiary, Comtech EF Data Corp., which is part of Comtech's Commercial Solutions segment, received a $1.6M order for DMD2050E Satellite Modems from a European Ministry of Defense, or MOD.

09:03 EDT Morningstar acquires Cuffelinks in Australia - Morningstar's Australian subsidiary Morningstar Australasia has acquired Cuffelinks, an independent, privately-owned publisher of investment commentary. Terms were not disclosed. As part of the acquisition, Graham Hand and Leisa Bell will join Morningstar. Cuffelinks, now branded as Firstlinks, was co-founded and, prior to the acquisition, solely owned by Hand, a market commentator in Australia with a network of industry contacts.

08:54 EDT ASGN completes $67M acquisition of Intersys - ASGN announced the completion of its acquisition of Intersys for $67M in cash. The acquisition deepens and expands ASGN's capabilities in digital innovation and enterprise solutions. Intersys will become part of ASGN's apex systems division. Intersys has developed a presence in the technology, consumer, healthcare and financial sectors through their solutions capabilities in the areas of data, analytics, digital, search, agile and cloud. Intersys anticipates approximately $31M in revenues for FY19 along with double-digit revenue growth in 2020. ASGN expects to realize revenue synergies by leveraging Intersys' robust capabilities to capture an increased portion of Apex's growing pipeline of consulting opportunities. In connection with the closing, ASGN granted restricted stock unit awards to 15 Intersys employees covering approximately 50,000 shares. Subject to continued service to the company, the grants will vest one-half on the second anniversary of the grant date, and 25% on each of the third and fourth anniversaries of the grant date. The restricted stock unit awards were granted to the Intersys employees as employment inducement awards pursuant to NYSE rules.

08:46 EDT CV Sciences announces expanded distribution partnership with The Vitamin Shoppe - CV Sciences announced further expansion of its PlusCBD Oil brand to a total of 515 The Vitamin Shoppe locations in 36 U.S. states and Puerto Rico. CV Sciences' expansion increases distribution and availability of a broad assortment of the Company's PlusCBD Oil products. Distribution across The Vitamin Shoppe's national footprint includes both topical products, such as PlusCBD Oil Extra Strength Balm and recently launched PlusCBD Oil Roll-On, as well as PlusCBD Oil full spectrum hemp extracts including Gold Formula Softgels, Gold Formula Drops, and Total Plant Complex Sprays and Capsules. The Company's PlusCBD Oil products began selling on September 22, 2019 at 383 The Vitamin Shoppe stores in 30 U.S. states and Puerto Rico. With the addition of 132 The Vitamin Shoppe stores across three states, CV Sciences' PlusCBD Oil products are now available at more than 5,500 retail locations throughout the U.S.

08:43 EDT ElectraMeccanica establishes wholly-owned China subsidiary - ElectraMeccanica Vehicles has established EMV Automotive Technology, a wholly-owned subsidiary, in China. As part of this strategic initiative, the first addition to EMV Automotive Technology is Larry Liang, the company's new Managing Director of China Production. Liang joins ElectraMeccanica as Managing Director of China Production with more than a dozen years of experience, previously holding positions as Deputy General Manager and Sr. Product Manager at companies such as DGENX, SAIC-GM, Siemens Automotive Electronics and PATAC. EMV Automotive Technology, Inc., will help the Company navigate Chongqing's favorable policies and geographical advantages, while assisting ElectraMeccanica in increasing the efficiency and effectiveness of quality control, automobile R&D and other necessary activities.

08:41 EDT Micron appoints Paul Marosvari as chief accounting officer - Micron Technology announced that the company has named Paul Marosvari as Micron's VP and chief accounting officer, reporting to David Zinsner, SVP and CFO. In this new position, Marosvari will oversee all accounting, controllership and financial reporting, including Sarbanes-Oxley controls. Since joining Micron in 1996, Marosvari has held several roles. Most recently, Marosvari was Micron's vice president and corporate controller.

08:39 EDT Honeywell expects to deliver on cash flow guidance for the year - Comments provided during Q3 earnings conference call.

08:38 EDT Genuine Parts CEO says performed 'in-line with our expectations' for Q3 - Paul Donahue, Chairman and CEO, commented, "Our third quarter results were highlighted by several accomplishments, including our achieving the $5 billion sales mark for the first time in the history of the Company. In addition, we were pleased to report positive comparable sales in our U.S., Canadian and Australasian automotive businesses as well as our Industrial operations, and we further improved our gross margin. This translated to operating margin expansion in the Industrial and Business Products segments, an improved overall margin performance and strong cash flows for the quarter." Donahue added, "Our team was also active executing on our strategy to further optimize our portfolio. We closed on the Inenco industrial acquisition and the Sparesbox ecommerce investment on July 1st, and we divested of Motion's Electrical Specialties Group on September 30th. We also made significant progress on our action plans to accelerate our ongoing cost savings efforts and develop expense reduction initiatives designed to more effectively address our cost structure, drive meaningful savings and deliver incremental value." Donahue concluded, "We were pleased to perform in-line with our expectations for the quarter and are committed to our growth strategy and cost savings initiatives over the near and longer terms. We believe our focus in these areas will serve to deliver improved results and create significant long-term value for our shareholders."

08:36 EDT Cisco appoints Carol Tome to board of directors - Cisco (CSCO) announced that Carol Tome has been nominated for election to its Board of Directors at the company's Annual Meeting of Shareholders on December 10. Current board member Steven West will be retiring at the end of his term on the date of the annual meeting. Tome served as Home Depot's (HD) CFO from May 2001 and executive vice president, Corporate Services from January 2007 until her retirement in August 2019.

08:34 EDT Genuine Parts reports Q3 SSS up 1.8% for Automotive Parts Group - Third quarter sales for the Automotive Parts Group were up 5.3%, including a 1.8% comparable sales increase, a 6.5% benefit from acquisitions and an unfavorable foreign currency translation of 1.8%. In addition, automotive sales were impacted by 1.2% due primarily to the sale of Grupo Auto Todo. Sales for the Industrial Parts Group were up 9.9%, including a 0.9% comparable sales increase and 9.0% from acquisitions. Sales for the Business Products Group were down 0.9%, consisting primarily of the change in comparable sales growth.

08:32 EDT Granite Oil to start recompletion program in 1Q20 - The company said, "Granite continues to test new ways to improve both the efficiency at which it adds oil production and the ultimate, long-term oil recovery of its large, 100%-owned, early-life-cycle Bakken oil pool through its gas injection enhanced recovery scheme and other complementary strategies. Over recent years, Granite has evolved its completion programs in parallel with its gas flood to optimize production rate and ultimate recovery of its development wells. As part of this evolution, the Company has tested progressively tighter frac spacing, having reduced from as high as 80 meters in 2015 down to approximately 26 meters on its most recent development well. Granite's four most recent development wells have been completed with average frac interval spacing of approximately 33 meters and have demonstrated consistently stronger production performance. With the success of increased frac density on new development wells, Granite has been evaluating the potential of a recompletion program to efficiently add production and increase the overall oil recovery of legacy producing wells originally completed with longer frac interval spacing.During the third quarter, Granite tested a recompletion program on a producing well originally completed in 2015 with average frac interval spacing of approximately 80 meters. The test consisted of 21 new frac stages added over a previously completed lateral length of approximately 700 meters. Interval spacing between new frac stages averaged approximately 25 meters, with average proppant tonnages of approximately 7.5 tons per stage. The initial test was conducted on a well in the gas flood area which was underpressured, allowing for more accurate quantification of results, and has increased production by approximately three-times relative to the pre-frac production rate over an extended testing period. The Company has identified 15 additional wells as recompletion candidates, with up to 12,000 meters of potential unstimulated lateral to be fracked. Of significant, compounding benefit is the Company's ability to utilize its gas injection EOR scheme to increase reservoir pressure prior to future operations in order to enhance production rates following the recompletions. Accordingly, in anticipation of the test results, the Company elected to keep five wells shut-in in a repressurized area during the third quarter for a future recompletions program. The significantly higher reservoir pressure in this area relative to the test well is expected to provide additional torque on the production rates of these wells. The Company will remain focused on its debt-reduction and efficiency goals through the remainder of 2019 and will commence a recompletion program in the first quarter of 2020. Granite is encouraged by the potential of future recompletions to accelerate its plans by strengthening the Company's ability to add producing barrels through this relatively low-risk capital operation. With over 80 potential infill drilling locations that will serve as the backbone of future development of its Bakken pool, the recompletion strategy provides an additional mechanism by which Granite can increase shareholder value in the current energy environment."

08:26 EDT Spring Bank reports results from first cohort of Inarigivir plus Vemlidy trial - Spring Bank Pharmaceuticals announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and pharmacodynamics of escalating doses of the investigational compound inarigivir co-administered with Gilead Sciences' Vemlidy for the treatment of chronic hepatitis B virus infection. This is the first data from a clinical trial examining the co-administration of inarigivir with a nucleoside analog in chronic HBV patients. In this Phase 2 trial, 30 patients with HBV infection received low-dose inarigivir 50mg plus Vemlidy for 12 weeks and 12 patients with HBV infection received Vemlidy alone for 12 weeks. Both arms will continue to receive Vemlidy alone for an additional 36 weeks. Interim top-line results from the first cohort indicate that, at week 12, 7 of the 30 patients in the inarigivir 50mg plus Vemlidy arm were HBsAg responders and met the primary efficacy study endpoint of having greater than or equal to 0.5 log IU/mL reduction in HBsAg from baseline. When excluding patients showing signs of an ALT flare prior to entering the study, 5 of the remaining 28 patients in this arm were HBsAg responders at week 12. In the inarigivir 50mg monotherapy cohort of the completed Spring Bank Phase 2 ACHIEVE trial, only 1 of 14 patients was a HBsAg responder at week 12. In the Vemlidy arm of this Phase 2 trial, 3 of the 12 patients were HBsAg responders. When excluding patients showing signs of an ALT flare prior to entering the study, only 1 of the remaining 10 patients in this arm was a HBsAg responder at week 12. The co-administration of inarigivir 50mg and Vemlidy was generally safe and well tolerated with no serious adverse events observed over the 12-week treatment period. Treatment-emergent adverse events ranged from mild to moderate in severity. Further analysis of the inarigivir 50mg plus Vemlidy cohort and evaluation of the safety, efficacy and pharmacodynamics of escalating doses of inarigivir co-administered with Vemlidy in HBV patients are ongoing. Interim top-line results from the remaining cohorts of the trial are expected in 2020.

08:22 EDT Alkaline Water forms A88 Infused Products for topical CBD products - The Alkaline Water Company announced the formation of A88 Infused Products Inc., a wholly-owned Nevada corporation. A88 Infused Products has developed a variety of topical CBD infused products which include salves, balms, lotions, essential oils, and bath-salts all made with lab-tested full-spectrum hemp. The Company intends to comply in full with all federal, state, and local laws, rules and regulations as the Company develops its CBD-infused products. The Company will not pursue the commercial production or sale of CBD-infused products until legally permitted. The Company is closely watching and responding to all regulatory developments within the FDA and in each individual U.S. state, and plans to launch its CBD infused products accordingly.

08:17 EDT IBM, Raw Seafoods partner to use blockchain for seafood traceability - IBM and Raw Seafoods announced a new collaboration connecting global sourcing partners, retailers, and restauranteurs who will begin using IBM Food Trust platform to enhance seafood traceability. Built on the IBM Blockchain Platform, the initiative will start by digitizing the supply chain for scallops sourced from the Atlantic Sea Scallop Fishery. The technology will address a number of problems, from widespread seafood fraud and mislabeling to the fact that few consumers know where their seafood actually comes from. The engagement was finalized in Q2.

08:15 EDT BeyondSpring granted U.S. patent for plinabulin - BeyondSpring announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,491 B2, for methods of treating a brain tumor by administering Plinabulin. The patent, which expires in 2036, covers methods for Plinabulin's use in the treatment of brain tumors, including metastatic brain tumor, with no approved chemotherapy on the market, and glioblastoma multiforme, the most common adult brain tumor. Both are known for their lethality and lack of response to treatment using the current standard of care. Dr. Lan Huang, BeyondSpring co-founder and CEO, is the inventor of the new patent. Only surgery and radiation, but no chemotherapy had ever been granted in metastatic brain tumor, with survival at around 4 to 6 months. Without the current advancement in primary tumor treatment, more patients would develop metastatic brain tumor with grim outcome. In recent years, there have been no substantial improvements in treatment options, and minimal improvements in the survival prospects for patients with GBM. The average life expectancy for GBM after symptoms onset is approximately 6 to 12 months. Plinabulin is currently in Phase 3 global clinical development for the treatment of non-small cell lung cancer and for the prevention of chemotherapy-induced neutropenia.

08:13 EDT CPI Aerostructures awarded $48M IDIQ re-winging contract from Boeing - CPI Aerostructures (CVU) announced the receipt of an Indefinite Delivery/Indefinite Quantity contract with a maximum ceiling value of $48M from Boeing (BA) for structural assemblies for the A-10 Thunderbolt II. Under the terms of the IDIQ, CPI Aero will manufacture major structural subassemblies of the A-10 aircraft's wing. The Company also announced that it has received initial purchase orders under the IDIQ contract valued at approximately $6M for the production of 4 shipsets of assemblies and associated program start-up costs. First delivery is expected to be in late 2020. CPI Aero further announced that Boeing has stated its intention to place additional firm production orders prior to May 2020 for between 23 and 40 production shipsets valued at between $9.1M and $14.7M with deliveries commencing in 2021.

08:09 EDT Can-Fite BioPharma to hold conference with 11 opinion leaders on Piclidenoson - Can-Fite BioPharma announced it is holding an International Advisory Board conference with a panel of eleven opinion leaders in rheumatoid arthritis from Austria, Switzerland and Spain focused on Piclidenoson. Gebro Pharma has licensed the distribution rights to Piclidenoson for the indications of rheumatoid arthritis and psoriasis in Austria, Switzerland and Spain. The purpose of the meeting, which is taking place in is to conduct a scientific review of Piclidenoson, the role of the Adenosidne receptor A3 and mechanism of action of the molecule and aspects related to patient populations. Can-Fite is currently enrolling 500 patients in Europe, Canada and Israel in a Phase III study of Piclidenoson as a first-line treatment for rheumatoid arthritis. The study will evaluate Piclidenoson as compared to placebo, and compared to methotrexate, the current standard of care for first-line treatment of rheumatoid arthritis.

08:09 EDT Union Pacific reports Q3 freight revenue declined 7% - Third quarter business volumes, as measured by total revenue carloads, decreased 8% compared to 2018. Growth in industrial volumes was more than offset by declines in agricultural products, premium and energy shipments. In addition: Quarterly freight revenue declined 7%, compared to third quarter 2018, as core pricing gains were offset by lower volumes, decreased fuel surcharge revenue and negative mix. Union Pacific's 59.5% operating ratio was an all-time best and improved 2.2 points, compared to third quarter 2018. The $2.09 per gallon average quarterly diesel fuel price in the third quarter 2019 was 12% lower than third quarter 2018. Quarterly freight car velocity was 213 daily miles per car, a 10 percent improvement compared to the third quarter 2018. Terminal dwell was 23.4 hours, a 20% improvement compared to third quarter 2018. Union Pacific's reportable personal injury rate was 0.82 per 200,000 employee-hours for the first three quarters 2019, compared to 0.77 for the same period 2018. The company repurchased 6.4M shares in the third quarter at an aggregate cost of $1.1B. Union Pacific also received 3.2M shares to complete a $2.5B Accelerated Share Repurchase program initiated in February 2019.

08:07 EDT Morgan Stanley CEO institutional securities business 'very resilient' - Says asset management "well positioned."

08:06 EDT American Axle opens new manufacturing facility in Barcelona - American Axle is opening a new manufacturing facility in the industrial area of Viladecans, Spain, just outside Barcelona. The new facility will support demand and growth from new and current European customers including Renault, BMW, Daimler, Porsche, Audi and Ford. AAM Barcelona produces a range of vibration control and damper products. The new facility consolidates two smaller facilities in nearby Gava and at full capacity will employ nearly 300 associates.

08:06 EDT Baker Hughes, a GE company changes name to Baker Hughes - Baker Hughes, a GE company (BHGE) announced its successful name change to Baker Hughes Company. The company will be known as Baker Hughes, and on Oct. 18, its Class A common stock will begin trading on the New York Stock Exchange under the symbol "BKR".

08:05 EDT Chaparral Energy, Bison enter 15-year water infrastructure agreement - Bison, Oklahoma's largest water infrastructure, logistics and solutions provider, announced that it has entered into a 15-year Water Gathering and Disposal Agreement with Chaparral Energy and its affiliates. Under the agreement, Bison will exclusively manage all of Chaparral's produced water infrastructure and water hauling logistics, including any future acreage acquired or operated by Chaparral, within a ~1.9M-acre dedicated area across Canadian, Grady and Blaine counties.

08:03 EDT Raytheon awarded $384M U.S. Army contract - Raytheon has been selected to provide the US Army with their next generation, 360-degree capable radar - the Lower Tier Air and Missile Defense Sensor. Raytheon will receive more than $384M to deliver six production representative units of the advanced LTAMDS radar under an Other Transactional Authority U.S. Army agreement. LTAMDS is a new radar that will ultimately replace the current U.S. Army's Patriot radars. It will operate on the Army's Integrated Air and Missile Defense network.

08:03 EDT Foamix announces FDA acceptance of NDA for FMX103 minocycline foam - Foamix Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for FMX103 topical foam. Foamix is seeking approval of FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults. The FDA has set June 2nd, 2020 as the Prescription Drug User Fee Act action date. The NDA submission is supported by the previously communicated results from two 12-week double-blind Phase 3 efficacy and safety trials and one 40-week open-label safety extension trial. In Studies FX2016-11 and FX2016-12, FMX103 met both co-primary endpoints, demonstrating statistically significant improvements in inflammatory lesion count and Investigator Global Assessment treatment success. No treatment-related serious adverse events have been identified in the FMX103 clinical development program, where the most common adverse event was upper respiratory tract infection. The NDA submission also incorporates information from Phase 1 and Phase 2 clinical trials, chemistry manufacturing and controls, and data from nonclinical toxicology studies.

07:47 EDT Gold Resource reports preliminary Q3 gold production of 11,165 ounces - Gold Resource Corporation reports record preliminary gold production results for the third quarter ended September 30, 2019 of 11,165 ounces, reflecting the growing gold production impact from its Isabella Pearl mine, located in Mineral County, Nevada. In addition, the Company reports preliminary third quarter production of 477,297 ounces of silver and significant copper, lead and zinc. With the Isabella Pearl project now in commercial production, Gold Resource Corporation has increased its 2019 global annual gold production outlook by 42% to 38,400 gold ounces, plus or minus 10 percent. Gold Resource Corporation is a gold and silver producer, developer and explorer with operations in Oaxaca, Mexico and Nevada, USA. The Company has returned $112 million to its shareholders in monthly dividends since commercial production commenced July 1, 2010 and offers its shareholders the option to convert their cash dividends into physical gold and silver and take delivery. Preliminary third quarter production from the Company's Oaxaca Mining Unit totaled 7,462 ounces of gold, 473,810 ounces of silver, 492 tonnes of copper, 2,459 tonnes of lead and 6,057 tonnes of zinc. Through the first three quarters of 2019, the Company's Oaxaca Mining Unit's preliminary production numbers total 21,881 ounces of gold, 1,304,975 ounces of silver, 1,407 tonnes of copper, 6,916 tonnes of lead and 17,949 tonnes of zinc. Preliminary third quarter production from the Company's Nevada Mining Unit totaled 3,703 ounces of gold. The Company announced on October 7, 2019 that the Isabella Pearl mine has reached commercial production levels. Since producing first gold in April 2019, the Isabella Pearl mine has produced approximately 5,381 ounces of gold through September 30, 2019. Fourth quarter 2019 gold production estimate for the Isabella Pearl mine targets 6,000 ounces, plus or minus 10 percent. The production ramp up at the Isabella Pearl mine is expected to continue over the next year. While quarterly production fluctuations are likely, production over the next several quarters is expected to increase to an approximate 40,000 gold ounce annual production rate estimated in late 2020. The Company maintains its 2019 Oaxaca Mining Unit Annual Production Outlook of 27,000 gold ounces and 1,700,000 silver ounces, plus or minus 10 percent. In addition, the Company's Nevada Mining Unit targets 6,000 ounces of gold production, plus or minus 10 percent, for the fourth quarter of 2019. This fourth quarter production target coupled with 5,381 gold ounces produced year-to-date, increases the Company's global 2019 annual gold production outlook to 38,400 ounces, plus or minus 10 percent.

07:41 EDT Marinus Pharmaceuticals presents Phase 2 clinical data on ganaxolone in RSE - Marinus Pharmaceuticals announced that results from its Phase 2 trial of ganaxolone in Refractory Status Epilepticus were presented at the Neurocritical Care Society 17th Annual Meeting in Vancouver, BC. The results were featured in an oral platform presentation by Henri Vaitkevicius M.D., investigator in the study. As previously disclosed, ganaxolone met the primary endpoint in the study with none of the 17 patients progressing to IV anesthetics within 24 hours of treatment initiation. A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic data, presented for the first time at the meeting today. The newly presented PK data show that the target dose of ganaxolone achieved plasma drug concentrations greater than 500 ng/mL for approximately 8 hours, the longest and highest duration of the three dosing groups. A dose response relationship among the dose groups was apparent, with the target dose demonstrating the best and most durable efficacy for the period beginning with commencement of the ganaxolone infusion through the 24-hour period that followed discontinuation of ganaxolone therapy. In addition, the targeted effective plasma concentrations were shown to be generally safe and well tolerated for this severely ill patient population, at concentrations at least 5 times higher than a previously studied neurosteroid. Previously reported key efficacy and safety findings: In 100% of patients, there was no escalation to IV anesthetics within 24 hours from infusion initiation. Target dose of ganaxolone was identified as 713 mg/day. For all patients who received the target dose of ganaxolone, there was no escalation to additional IV AEDs or IV anesthetics for seizure or status relapse at any time during ganaxolone administration and through the 24-hour follow-up period. Median time to status cessation was 5 minutes. Ganaxolone was shown to have an acceptable safely profile for the RSE patient population in all dose groups. The safety profile is consistent with ganaxolone's known mechanism of action.

07:35 EDT Stealth Biotherapeutics' elamipretide shows 27% increase in cardiac volume - Stealth BioTherapeutics announced the presentation of new data from the open-label extension portion of the Phase 2/3 Tazpower study evaluating elamipretide in patients with Barth syndrome. The findings, presented at the American Society of Human Genetics 2019 Annual Meeting, showed that treatment with elamipretide resulted in a 27% increase in average cardiac stroke volume, or the amount of blood pumped by the heart's left ventricle per contraction, from the trial baseline - 40.8 mL - to week 36 - 51.8 mL - of the open-label extension. Barth syndrome is an ultra-rare mitochondrial disease associated with skeletal muscle weakness, debilitating fatigue, cardiac abnormalities, recurrent infections and delayed growth. Life expectancy is reduced due primarily to heart disease. Elamipretide demonstrated potential to improve measures of exercise performance, strength and patient- and clinician-reported outcomes.The FDA has granted Fast Track and Orphan Drug designations for elamipretide for the treatment of Barth syndrome.

07:33 EDT Morgan Stanley reports Q3 equities trading revenue $1.99B

07:32 EDT Morgan Stanley reports Q3 ROE 11.2%, ROTCE 12.9% - James P. Gorman, Chairman and CEO, said, "We delivered strong quarterly earnings despite the typical summer slowdown and volatile markets. Firmwide revenues were over $10B for the third consecutive quarter, and we produced an ROE within our target range. Our consistent performance shows the stability of our business model. We remain committed to controlling our expenses and are well positioned to pursue our growth initiatives." Book value and Tangible book value increased 12% year-over-year. Institutional Securities net revenues at $5B reflects strength across products, characterized by strong client engagement despite seasonality and volatile markets. Wealth Management delivered a pre-tax margin of 28.4% on continued expense discipline.

07:22 EDT Centennial Resource Development appoints Steven Shapiro to board of directors - Centennial Resource Development announced that Steven Shapiro has been appointed to its Board of Directors, effective immediately. Shapiro will serve as a member of the Audit and Compensation Committees. Shapiro is currently a Senior Advisor to Outfitter Energy Capital and serves on the Advisory Board for Pickering Energy Partners LP.

07:11 EDT Philip Morris backs FY19 currency-neutral net revenue growth of at least 6% - Lowers FY19 capital expenditure view to about $1.0B from $1.1B prior forecast. Raises FY19 operating income margin view to about 150bps from prior forecast of 100bps. Lowers FY19 operating cash flow view to about $9.2B from prior forecast of $9.5B.

07:08 EDT Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" - Prior guidance was "down approximately 1%." The company cites "the impact of earlier-than-initially-anticipated price increases in select markets."

07:05 EDT BridgeBio reports preclinical data on infigratinib in treating achondroplasia - BridgeBio Pharma and subsidiary QED Therapeutics announced the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia during the American Society of Human Genetics 2019 Annual Meeting. Achondroplasia is the most common cause of dwarfism and is caused by mutation of the gene for fibroblast growth factor receptor 3 or FGFR3, which has been shown to be crucial for the process of bone elongation. Infigratinib, an investigational agent, binds to FGFR3 and has been previously shown to increase bone growth in preclinical mouse models of achondroplasia.3 The data presented today showed a positive dose-response relationship between infigratinib and bone growth. In each of the three dose groups, treatment with infigratinib led to an increase in all nine measures of bone size studied compared to the control group. No apparent toxicity of infigratinib was noted in this study. The data supports the decision to submit an investigational new drug application to the FDA and initiate a clinical trial in 2020 to investigate the potential to treat children with achondroplasia.

07:02 EDT Auryn Resources stakes additional claims at Sombrero North project area - Auryn Resources announced that it has staked 8,500 hectares of additional ground at the Sombrero North project area. The newly acquired claims, Macha Machay, contain the highest copper values in stream sediments observed through Auryn's regional exploration program, which screened approximately 7,000 square kilometers of land on the western extension of the world-class Andahuaylas-Yauri belt. Ivan Bebek, Executive Chairman & Director, commented: "In an effort to be ambitious as first movers on the western half of the Andahuaylas-Yauri belt, we have taken low-cost initiatives to secure more highly prospective claims prior to drilling the Sombrero Main target in Q1 2020. The regional stream sediment survey results from Macha Machay contain the strongest geochemical values we've seen to date. The new claims are also adjacent to our high-grade Milpoc target and importantly, are within the Hunacasancos community land where we have an existing agreement to conduct exploration. In the coming weeks we look forward to results from the seven hole summer drill program at Committee Bay in the Arctic, extensive targeting results from Homestake Ridge in B.C. and our surface sampling program currently underway at Curibaya in Southern Peru."

06:58 EDT PPG CEO says 'we made excellent progress executing on our key initiatives' - "We delivered strong adjusted earnings per share growth of 15% compared to the prior year quarter, as we continue to build momentum and remain focused on operating margin recovery. Strong execution against our cost-savings initiatives and our sixth consecutive quarter with selling price increases of at least 2% aided in our gross profit improvement, as we continue our efforts to offset the significant raw material cost inflation absorbed in the past few years," said Michael McGarry, PPG chairman and CEO. "Our earnings growth came despite notable weakening in industrial production, which was broad - both geographically and by end-use market - and which more significantly impacted our general industrial and automotive OEM coatings businesses. Consistent with our recent quarterly trends, the aerospace coatings and protective and marine coatings businesses posted strong sales growth." "We made excellent progress executing on our key initiatives, including $20 million of cost savings in the third quarter related to previously announced cost savings programs," said McGarry. "In addition, we completed the acquisition of Dexmet, a manufacturer of specialty materials for aerospace, automotive and industrial applications. We have completed four acquisitions with combined annual revenues of about $400 million that are benefiting our results this year. We continue to generate strong operating cash flow, with year-to-date cash generation improving by about $600 million in comparison to last year."

06:56 EDT GeoPark reports Q3 operational results - GeoPark reported an operational update for Q3. Q3 consolidated oil and gas production was up 6% to 39,619 boepd - adjusting for divestments, consolidated production up 9%, 3% higher than Q2. Oil production increased by 8% to 33,693 bopd; Colombian oil production increased by 8% to 31,394 bopd or12% increase adjusting for divested blocks; Chilean production increased by 27% to 3,358 boepd. In Colombia on the Llanos 34 block, GeoPark operated, 45% WI, a new Guaco oil field was discovered along the most western fault trend in block potentially opening-up new trend, five new wells were tested and put on production in block, new wells drilled and tested are currently producing more than 3,600 bopd gross. In Brazil, on the REC-T-128 block, GeoPark operated, 70% WI, the new discovered Praia dos Castelhanos oil field initiated long-term testing at rate of approximately 200-220 bopd and high Potential Acreage Expansion. The company accelerated its share buyback program, having acquired 4,404,000 shares, 7% of total outstanding shares, for $72.0M since December 2018.

06:51 EDT Golden Minerals enters option agreement to sell Santa Maria Project - Golden Minerals announced that it has entered into an option agreement to sell its right to acquire a 100% interest in the Santa Maria silver and gold project located in southern Chihuahua State, Mexico to Magellan Gold. The agreement provides for a period of up to 150 days during which Magellan will complete its due diligence review and secure adequate financing for the project. Prior to the end of such period, Magellan will have the right to exercise its option to acquire the Company's interests in the project. If Magellan exercises its option, Magellan will pay $1M cash to Golden Minerals at closing. Golden Minerals will retain a 6.5% NSR royalty from all production at Santa Maria until a total of $3M has been paid to the company under the royalty agreement. Thereafter, Golden will retain a 3.0% NSR royalty for the balance of the mine's life. If Magellan fails to achieve commercial production from the project within one year following closing, Golden Minerals will not be obligated to convey its interests in the project to Magellan and the company will retain its interest in the project with no obligation to return any payments to Magellan. Golden Minerals' President and CEO, Warren Rehn, notes, "We feel this is a very positive transaction for Golden Minerals. It will let us monetize Santa Maria's value while keeping our risk to a minimum. The ongoing cash stream that this transaction presents will be used to further some of Golden's other exploration projects."

06:46 EDT BWX Technologies awarded $806M contract from U.S. Navy - BWX Technologies announced that the U.S. Naval Nuclear Propulsion Program has awarded subsidiary BWXT Nuclear Operations Group, a contract with options totaling approximately $806M for the procurement of long-lead materials required for the manufacture of naval reactor components. The base material procurement contract for fiscal year 2019 is valued at $75M and is the first of seven annual options available through 2025. The remaining six options have an average annual value of about $122M, contingent on U.S. congressional appropriations.

06:38 EDT Neptune Wellness to provide extraction services to farming services operation - Neptune Wellness announced that it entered into an agreement to provide extraction services to a U.S.-based farming services operation. Under the contract terms, Neptune will receive hemp biomass to be processed and transformed into crude oil extracts. The two-year agreement could reach a total value in excess of $20M. The first shipment of biomass is expected to arrive at Neptune's North Carolina facility in the coming weeks. Once Neptune's near-term capacity expansion plans are complete and the Canadian expansion approved by Health Canada, the company is expected to have a total extraction capacity of 3,000,000 kg of biomass annually, spread equally between Canada and the U.S.

06:37 EDT Snap-On sees 2019 CapEx $95M-$105M - Sees 2019 effective income tax rate comparable to FY18 effective tax rate of 24.0%.

06:34 EDT New Age Beverages partners with Nestle to relaunch NESTEA in U.S. - New Age Beverages (NBEV) announced the expansion of their partnership with Nestle (NSRGY), including the broadening of their license agreement on NESTEA to now include all products under the brand, including NESTEA Powdered Tea products in the United States. As a result, New Age is launching NESTEA Powders immediately in its e-commerce system, targeting its current database of more than 1M consumers, and with major retailers through the United States. NESTEA Powdered Tea has historically generated sales at retail of more than $30M. The Coca-Cola Company (KO) used to own the NESTEA license for ready-to-drink beverages, the same license New Age now has within the U.S. Both NESTEA ready-to-drink and powdered teas have a large base of passionate, loyal consumers across the country with brand awareness of 89%, the largest of any brand in New Age's portfolio. According to Nielsen, the powdered tea segment in the United States is valued at $259M for the latest 52-week period. New Age intends to capture a significant share of the market, leveraging NESTEA's awareness and consumer loyalty, and will make the brand available through its own direct-store-distribution system, its network of distributor partners throughout the U.S., and its footprint with major retailers throughout the country.

06:12 EDT McEwen Mining reports Q3 production 45,930 gold equivalent ounces - McEwen Mining reported consolidated Q3 production of 35,043 gold ounces and 947,146 silver ounces, or 45,930 gold equivalent ounces using the average gold:silver price ratio for Q3 of 87:1. The Gold Bar Mine continued to improve during Q3, achieving several performance benchmarks for ore production, crushing throughput, and gold production. Gold Bar produced produced 11,029 gold ounces in Q3, in line with the plan and approaching the designed capacity of the process plant. The San Jose and El Gallo mines met their production targets. San Jose is on-track to achieve 2019 guidance of 49,000 gold ounces and 3,225,000 silver ounces. Black Fox produced 7,421 gold ounces in Q3. Production was below expectations, primarily because of insufficient working areas and delays in advancing underground development. Exploration drilling from Stock East returned intercepts such as: 83.5 g/t gold over 5.6 m, including 417 g/t over 1.1 m; and 34.7 g/t gold over 5.9 m, including 74.1 g/t over 2.7 m.

06:06 EDT Ford introduces North America's largest electric vehicle charging network - Ford (F) is offering its all-electric vehicle customers North America's largest electric vehicle public charging network, with more than 12,000 places to charge, including fast charging, and more than 35,000 charge plugs - more than any other automotive manufacturer, addressing a big concern for those switching to all-electric cars. New Ford all-electric vehicles, including the Mustang-inspired SUV arriving next year, will come standard with a Ford Mobile Charger that can charge regardless of outlet power (120- and 240-volt outlets); for those with longer commutes or who want greater peace of mind, a Ford Connected Charge Station can fully power a vehicle overnight while they sleep. Ford is collaborating with Amazon (AMZN) in the U.S. for all your installation services - from 240V outlets to the Ford Connected Charge Station. Through FordPass on a mobile device or in each vehicle's on-screen dashboard, customers will be able to monitor charging at home, and easily find and pay for easy, one-stop charging at FordPass Charging Network stations.

05:24 EDT Verona completes enrollment in nebulized ensifentrine Phase 2b clinical trial - Verona Pharma announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease, COPD.